New FeiginLab paper is OUT! A commonly prescribed anti-anxiety drug reduces inflammatory signaling in pancreatic cancer through regulation of cancer-associated fibroblast activity!
aacrjournals.org/cancerrescom...
Don’t miss our featured posters for Monday, April 20—highlighting even more critical discoveries from Roswell Park. See you at AACR!
#AACR26
Repeated cloning cannot be sustained indefinitely in mammals, according to a 20-year study in mice published in Nature Communications. The results suggest that sexual reproduction is necessary to eliminate large-scale genetic mutations that can accumulate in mammalian clones. 🧬 🧪
WATCH: Emese Zsiros, MD, PhD, FACOG, of @roswellpark.bsky.social, discusses the @fda.gov approval of pembrolizumab plus paclitaxel with or without pembrolizumab for PD-L1–positive ovarian cancer. #gyncsm #oncology
www.onclive.com/view/dr-zsir...
For readers interested in drug repurposing, this review summarizes the approaches, evaluates available in silico resources and presents case studies
www.nature.com/articles/s41...
rdcu.be/e60em
Thank you to the Sinclair Cancer Research Institute at Queens University for hosting my visit this week. It was fantastic to share our science from Roswell Park and to meet with so many investigators and trainees. @sinclaircri.bsky.social @queensuresearch.bsky.social @roswellpark.bsky.social
Review @natrevdrugdiscov.nature.com
Therapeutic targeting of neuroimmune mechanisms in neurodegeneration
www.nature.com/articles/s41...
Follow up to Doug Hanahan’s visionary article about the stages of cancer development from back in the 1990s
www.cell.com/cell/fulltex...
Thank you to the American Cancer Society for highlighting our lab, this means a great deal.
Please join the Making Strides Against Breast Cancer Fundraiser October 17, 2026
www.facebook.com/groups/makin...
The New England Journal of Medicine ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer A Research Summary based on Powles T et al. | 10.1056/NEJMoa2511885 | Published on October 20, 2025 Visual representations of the patients in the trial and the treatments they were assigned. Read the full Research Summary at NEJM.org.
In muscle-invasive bladder cancer, ctDNA-guided atezolizumab led to longer disease-free survival (9.9 vs. 4.8 months), as well as to longer overall survival (32.8 vs. 21.1 months), than placebo among ctDNA-positive patients. Full IMvigor011 phase 3 trial results and Research Summary: nej.md/3WIRtEg
Fig 2. Constraints related to the patient, the pharmacy, and the outpatient infusion centers to be taken into account when concentrating outpatient ICI administrations in a stipulated time window in the morning. ICI, immune checkpoint inhibitor. Pharmacy constraints: physiochemical stability, risk of waste. Patient: distance home-hospital, diurnal preference. Day unit: priority rankings, long multi drug regimens.
Proposed Action We propose the following approaches to make early ToDA of ICI feasible in daily routine practice: • ASSESS: establish a nurse-led telephone assessment on the eve of ICI administration with full blood work-up available to confirm clinical and biologic permissiveness to ICI treatment; • AVOID (as far as possible and according to the habits of each center): do not schedule medical consultation and ICI treatment on the same day to reduce risks of delays in treatment administration (prefer teleconsultations the day before treatment for patients living far from the center); • ALWAYS administer ICI first when in combination with IV chemotherapy or other agents, unless reverse sequencing is recommended; • ALLOCATE: prioritize two or three ICI mornings per week and save the remaining two or three mornings for long-term combination treatments not including ICIs; • ANTICIPATE: whenever possible, cytotoxic reconstruction units could prepare ICIs in the evening of the eve so that they are ready to be administered early on the following morning.
🌅 Several studies have suggested checkpoint inhibitors dosed AM may be assoc w/ improved outcomes- but strong risk of confounding.
Out now in #JCOOP: review of literature & discussion of how practices could actually implement this. Suspect will be very dependent on local AM traffic!
#Review 🕯️🕯️🕯️
The ability of #macrophages to eliminate cancer cells is controlled by phagocytic checkpoints. Veillette&Co discuss targeting these checkpoints for cancer therapy and outline strategies to address therapeutic efficacy concerns.
📖⬇️
How can senescent cells, which are damaged and growth arrested, both block tumor initiation as well as fuel its growth? A recent study published in Cancer Discovery @aacrjournals.bsky.social from Lin Zhou in the lab uncovered some new insights into this puzzle.
aacrjournals.org/cancerdiscov...
For readers interested in cancer therapies, this Review in the October issue discusses how metabolic modulators and dietary nutrients can improve the anticancer immune response and overcome drug resistance mechanisms
rdcu.be/eLS8A
www.nature.com/articles/s41...
🚀 NY-CURES Launch — Championing State-Wide Investment in Science! 🚀
Our new coalition advocates for sustained public support of New York’s vibrant biomedical research ecosystem — creating cures, economic gains & strengthening communities.
Sign up. Stay informed. Join the movement: www.nycures.org/
Endothelial-like cancer-associated fibroblasts facilitate pancreatic cancer metastasis via vasculogenic mimicry and paracrine signalling 🧪 #PancreaticCancer gut.bmj.com/content/74/9...
